Solvias to Present at ASGCT on Safer Gene Therapy Innovations
This discussion aims to enhance early risk detection, ensure regulatory compliance, and promote safer, more effective therapies in cell line development.
On May 6, 2025, Solvias announced that Dr. Daniel Galbraith, its Chief Scientific Officer, will present at the American Society of Cell and Gene Therapy (ASGCT) 28th Annual Meeting scheduled for May 13-17, 2025. This significant event gathers thousands of experts, including scientists, clinicians, industry leaders, and patient advocates, to discuss and showcase groundbreaking research and advancements in cell and gene therapy.
The session titled "Targeted Locus Amplification (TLA): Meeting Regulatory Demands for Safer Lentiviral Vectors" emphasizes the critical role of early genomic analysis in ensuring the safety of gene therapies utilizing lentiviral vectors (LVV). With regulatory agencies intensifying their scrutiny over risks like insertional mutagenesis, Dr. Galbraith will highlight how TLA enhances Investigational New Drug (IND) applications through its superior ability to provide detailed mapping of integration sites and vector characterization.
Dr. Galbraith noted, "As gene and cell therapies evolve towards more extensive clinical applications, the need to ensure vector safety becomes increasingly crucial. Regulatory bodies are posing more complex questions, and we must be equipped with informed responses. TLA enables us to identify integration risks early on, facilitating data-driven decisions that not only fulfill regulatory requirements but also prioritize the safety and effectiveness of therapies. I eagerly anticipate engaging with peers at ASGCT to discuss how we can hasten the development of such therapies while placing patient safety at the forefront of our efforts."
Details of the Presentation Session
During the presentation at ASGCT, the following details will be addressed:
- Presentation Session: Moving Lentiviral Vectors Through the Investigational New Drug (IND) Process
- Presentation Topic: Lentivirus Integration and Mechanisms; Targeted Locus Amplification Platform
- Presentation Date/Time: Tuesday, May 13, 2025, from 9:55 to 10:25 AM CT
- Location: Room 265-268
Solvias continues to innovate in providing safe and effective cell and gene therapies by integrating cutting-edge technologies with profound scientific knowledge. The newly established Center of Excellence in Cell and Gene Therapy, which was launched earlier this year, strengthens the company’s resolve to advance transformative treatments for conditions such as cancer and rare diseases. This facility aims to bring essential analytical services closer to biotech companies in the U.S., thereby expediting their journey toward clinical success.
About Solvias
Solvias is recognized as a global leader in chemistry, manufacturing, and control (CMC) analytics for the life sciences sector. With a team of experts boasting extensive regulatory knowledge across a spectrum of small molecules, biologics, and cell and gene therapies, Solvias provides comprehensive solutions that span from raw material testing to drug product release and active pharmaceutical ingredient (API) development. Headquartered near Basel, Switzerland, Solvias operates six Centers of Excellence worldwide, all of which comply with the highest ISO, GMP, GLP, and FDA standards. For more insights, please visit solvias.com.
Media Contact Information
Katy McGirr, Director of Global Marketing
+1 617 513 8287
Frequently Asked Questions
What significant topic will Solvias discuss at ASGCT?
Solvias will present on the importance of Targeted Locus Amplification in ensuring the safety of lentiviral vector gene therapies.
When is the ASGCT Annual Meeting taking place?
The ASGCT Annual Meeting will occur from May 13-17, 2025.
Who will be representing Solvias at the conference?
Dr. Daniel Galbraith, the Chief Scientific Officer, will represent Solvias during the presentation.
Where will the presentation be held during the event?
The presentation will take place in Room 265-268.
What is the purpose of the newly opened Center of Excellence?
The Center aims to enhance the development of safer therapies for cancer and rare diseases and provide closer analytical services to U.S. biotech firms.
